Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Zimmer Biomet logoZimmer Biomet ZBH

The company said fourth-quarter net sales for Q4 2023 rose 6.3% to $1.940 billion (6.1% on a constant currency basis), and full-year net sales rose 6.5% to $7.394 billion (7.5% on a constant currency basis).

8-KResults of Operations and Financial ConditionFiled Period of report Summary published (UTC)

Key points

AI summary
  1. The company said fourth-quarter net sales for Q4 2023 rose 6.3% to $1.940 billion (6.1% on a constant currency basis), and full-year net sales rose 6.5% to $7.394 billion (7.5% on a constant currency basis).

  2. The company said net earnings for Q4 were $419.2 million ($458.1 million on an adjusted basis), and full-year net earnings were $1.024 billion ($1.584 billion on an adjusted basis). It said full-year diluted earnings per share were $4.88, and adjusted diluted earnings per share were $7.55.

  3. The company provided full-year 2024 guidance, projecting reported revenue change of 4.5% to 5.5%, constant currency revenue change of 5.0% to 6.0%, and adjusted diluted EPS of $8.00 to $8.15. It expects a foreign currency exchange impact of (0.5)%.

  4. The company said it started a global restructuring program in late 2023 and expects approximately $200 million in annual run rate cost savings as it exits 2025. It also said it completed a $500 million share buyback program in January 2024.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

Q4 2023 and Full-Year Net Sales

The company said fourth-quarter net sales for Q4 2023 rose 6.3% to $1.940 billion (6.1% on a constant currency basis), and full-year net sales rose 6.5% to $7.394 billion (7.5% on a constant currency basis).

Source · Based on the filing body and exhibits

Q4 and Full-Year Net Earnings and Diluted EPS

The company said net earnings for Q4 were $419.2 million ($458.1 million on an adjusted basis), and full-year net earnings were $1.024 billion ($1.584 billion on an adjusted basis). It said full-year diluted earnings per share were $4.88, and adjusted diluted earnings per share were $7.55.

Source · Based on the filing body and exhibits

Full-Year 2024 Outlook (Guidance)

The company provided full-year 2024 guidance, projecting reported revenue change of 4.5% to 5.5%, constant currency revenue change of 5.0% to 6.0%, and adjusted diluted EPS of $8.00 to $8.15. It expects a foreign currency exchange impact of (0.5)%.

Source · Based on the filing body and exhibits

Restructuring Program and Share Buyback

The company said it started a global restructuring program in late 2023 and expects approximately $200 million in annual run rate cost savings as it exits 2025. It also said it completed a $500 million share buyback program in January 2024.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.